MapLight Therapeutics, Inc. Common Stock (MPLT) Stock
Key stats
- Market cap
- $415.71M
- Price / Earnings ratio
- -1.5x
- EPS (TTM)
- $47.30
- Volume
- Loading
- 52-week high
- $40.43
- 52-week low
- $6.06
- EPS vs analyst estimate
- -2633.8%Q3 FY25 · -$37.18 vs -$1.36
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with MPLT
Recent news

Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)
MPLT

Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround
Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround
MPLT

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
MPLT

Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint
Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint
MPLT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 42.13
- MACD 12/26/9
- -0.70
- EMA 9 of MACD
- -0.86
- MACD histogram
- 0.15
- SMA 50
- $9.58
- Price below SMA 50
- EMA 50
- $9.96
- Price below EMA 50
- SMA 200
- $20.08
- Price below SMA 200
- EMA 200
- $16.93
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.86 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)
MPLT

Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround
Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround
MPLT

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
MPLT

Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint
Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint
MPLT

MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
MPLT

MapLight's schizophrenia drug fails once-daily test, shares plunge
MapLight's schizophrenia drug fails once-daily test, shares plunge
MPLT

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More
Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More
MPLT

MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut
MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut
MPLT
News tone: automated (AI) classification of the article's content, not a price prediction.
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders. The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Its discovery platform has the potential to fill this gap by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D. | Founder, President, CEO & Director | 1968 |
| Mr. Jonathan Gillis CPA | Chief Admin & Acc Officer, PAO, Interim CFO & PFO | 1981 |
| Dr. Robert C. Malenka M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1955 |
| Dr. Erin Pennock Foff M.D., Ph.D. | Chief Medical Officer | 1977 |
| Dr. Karoly Nikolich Ph.D. | Founder & Member of Advisory Board | 1948 |
| Dr. Karl Deisseroth M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Dr. James Woodruff Lillie Ph.D. | Chief Scientific Officer | 1956 |
| Mr. Kristopher L. Hanson J.D. | General Counsel & Secretary | 1972 |
| Dr. Anatol Kreitzer Ph.D. | Chief Discovery Officer | 1975 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 42.13
- MACD 12/26/9
- -0.70
- EMA 9 of MACD
- -0.86
- MACD histogram
- 0.15
- SMA 50
- $9.58
- Price below SMA 50
- EMA 50
- $9.96
- Price below EMA 50
- SMA 200
- $20.08
- Price below SMA 200
- EMA 200
- $16.93
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $43.00
- Average
- $43.00
- High
- $43.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -7.7 | -19.4 | +29.3 | |||||||||
| 2026 | +5.5 | -3.7 | +15.5 | +53.0 | -4.5 | +20.4 | -63.9 | +3.3 | -23.4 | -21.3 | +10.3 |



